Abstract
The evolutions in treatments and clinical practices in organ transplantations led to modifications in the therapeutic drug monitoring (TDM) of immunosuppressive drugs. A focus is made regarding the C2 sampling of cyclosporin, as well as the TDM of mycophenolate mofetil and sirolimus. A review of literature about the evolution of drug monitoring, technical methods and sampling strategies is described. Arguments in favour of TDM are thus a decrease in the frequency of both graft rejection and adverse drug reactions, however, new strategies or new targets are needed in new associations or indications.
MeSH terms
-
Biological Availability
-
Chromatography, High Pressure Liquid
-
Cyclosporine / pharmacokinetics*
-
Drug Monitoring / methods*
-
Drug Monitoring / standards
-
Enzyme Multiplied Immunoassay Technique
-
Graft Rejection
-
Heart Transplantation
-
Humans
-
Immunosuppressive Agents / pharmacokinetics*
-
Kidney Transplantation
-
Liver Transplantation
-
Mycophenolic Acid / analogs & derivatives
-
Mycophenolic Acid / pharmacokinetics*
-
Patient Selection
-
Reproducibility of Results
-
Sirolimus / pharmacokinetics*
-
Time Factors
-
Transplantation Immunology
Substances
-
Immunosuppressive Agents
-
Cyclosporine
-
Mycophenolic Acid
-
Sirolimus